ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
ACELYRIN Inc

ACELYRIN Inc (SLRN)

4.03
-0.05
(-1.23%)
At close: June 24 4:00PM
4.03
-0.01
( -0.25% )
After Hours: 4:39PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
4.03
Bid
4.03
Ask
4.66
Volume
1,107,552
4.02 Day's Range 4.19
3.91 52 Week Range 29.88
Market Cap
Previous Close
4.08
Open
4.08
Last Trade
50
@
4.03
Last Trade Time
16:51:08
Financial Volume
$ 4,532,500
VWAP
4.0924
Average Volume (3m)
900,548
Shares Outstanding
99,026,983
Dividend Yield
-
PE Ratio
-1.05
Earnings Per Share (EPS)
-3.85
Revenue
-
Net Profit
-381.64M

About ACELYRIN Inc

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in... Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
ACELYRIN Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SLRN. The last closing price for ACELYRIN was $4.08. Over the last year, ACELYRIN shares have traded in a share price range of $ 3.91 to $ 29.88.

ACELYRIN currently has 99,026,983 shares outstanding. The market capitalization of ACELYRIN is $400.07 million. ACELYRIN has a price to earnings ratio (PE ratio) of -1.05.

SLRN Latest News

ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024

LOS ANGELES, June 05, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative...

ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024

Lonigutamab is the first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease (TED) patients LOS ANGELES, May 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq:...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.11-2.657004830924.144.393.958829974.11101895CS
4-0.15-3.588516746414.1853.919250784.20101891CS
12-2.73-40.38461538466.766.813.919005484.75872639CS
26-3.09-43.39887640457.128.8853.9110786976.48048774CS
52-14.05-77.710176991218.0829.883.91113612410.5034879CS
156-18.97-82.47826086962329.883.91109642111.47935068CS
260-18.97-82.47826086962329.883.91109642111.47935068CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GLYCGlycoMimetics Inc
$ 0.46
(72.54%)
18.73M
SNTISenti Biosciences Inc
$ 0.3762
(49.29%)
9.3M
LGHLWLion Group Holding Ltd
$ 0.0094
(38.24%)
100
ODPODP Corporation
$ 47.52
(21.85%)
8.14k
CDXCChromaDex Corporation
$ 3.04
(19.22%)
1.91k
HGASGlobal Gas Corporation
$ 0.7101
(-27.54%)
56.17k
XAIRBeyond Air Inc
$ 1.0101
(-24.62%)
435.98k
MLGOMicroAlgo Inc
$ 11.58
(-22.80%)
4.08M
LGOLargo Inc
$ 1.66
(-14.87%)
2.02k
LIPOLipella Pharmaceuticals Inc
$ 0.54
(-14.56%)
308.78k
GLYCGlycoMimetics Inc
$ 0.46
(72.54%)
18.73M
NVDANVIDIA Corporation
$ 117.07
(-0.88%)
15.3M
SNTISenti Biosciences Inc
$ 0.3762
(49.29%)
9.3M
CRKNCrown Electrokinetics Corporation
$ 0.0364
(-4.96%)
6.3M
MLGOMicroAlgo Inc
$ 11.58
(-22.80%)
4.08M

Your Recent History

Delayed Upgrade Clock